Type 2 Diabetes and NASH: Which One Causes the Other?

Your doctor told you that your fatty liver and your diabetes are connected. But they did not explain which came first or whether treating one helps the other. 

And you are left with the unsatisfying sense that two major diagnoses are somehow circling each other without a clear explanation.

The honest answer is that NASH and type 2 diabetes cause each other  in a metabolic feedback loop that amplifies both conditions simultaneously. Understanding this loop is the key to managing both effectively. 

For comprehensive NASH diabetes treatment in Pune, Dr. Bipin Vibhute at thelivertransplant.com provides specialist evaluation of the metabolic-liver disease relationship. Visit thelivertransplant.com to book your assessment.

Key Takeaways:

• The bidirectional mechanism  how NASH causes diabetes and diabetes causes NASH
• Why hepatic insulin resistance is the linchpin of both conditions
• Why so many Indian patients develop NASH at lower BMI than Western populations
• What the combined effect of NASH and diabetes does to liver cancer risk
• Which diabetes medications actually help the liver  and which ones don’t

How Are NASH and Type 2 Diabetes Connected?

This is a genuine two-way relationship  not a simple case of one causing the other.

• The Conventional Direction: Diabetes Driving NASH

Insulin resistance  the hallmark of type 2 diabetes, disrupts normal fat metabolism throughout the body. When cells become resistant to insulin’s signal, the liver compensates by increasing fat synthesis.

Hepatic de novo lipogenesis (the liver’s fat-manufacturing process) is normally regulated by insulin. In insulin resistance, this regulation breaks down. The liver produces fat continuously, regardless of dietary intake, leading to progressive hepatic steatosis.

Hyperinsulinaemia  the high insulin levels that characterise early type 2 diabetes, further stimulates fat production. Glucose toxicity from persistently elevated blood sugar damages hepatocytes (liver cells) directly, adding a cytotoxic insult on top of the metabolic fat accumulation.

The result: patients with type 2 diabetes have NASH at rates of 50–70%, compared to approximately 20–30% in the general population.

• The Reverse Direction: NASH Causing Diabetes

This direction is equally important and less often discussed.

The liver is the primary organ responsible for glucose production between meals (hepatic gluconeogenesis) and for clearing glucose after meals (through glycogen synthesis and glucose oxidation). These processes are regulated by insulin signaling within the liver.

When liver fat accumulates, as in NASH, hepatic insulin signaling is impaired. The liver continues producing glucose even when insulin tells it to stop  a condition called hepatic insulin resistance.

This hepatic glucose overproduction is one of the primary drivers of fasting hyperglycemia in early type 2 diabetes. The fatty liver is literally manufacturing the elevated morning blood sugar that characterises early type 2 diabetes.

For patients trying to understand how this fat accumulation begins and what metabolic conditions create it, How Does Obesity Lead to Fatty Liver Disease? covers the mechanistic link between visceral fat, insulin resistance, and hepatic steatosis in accessible clinical terms. 

In patients with NASH who do not yet have diabetes, hepatic insulin resistance is already present and measurable  predating the pancreatic beta cell failure that eventually produces frank diabetes. 

NASH is not just a consequence of metabolic syndrome  it is an active contributor to its progression.

Which Comes First  The Liver or the Diabetes?

In most patients, hepatic fat accumulation precedes the formal diagnosis of type 2 diabetes by years.

• The Ectopic Fat Sequence

Ectopic fat is fat deposited in organs that are not designed to store it  the liver, the pancreas, the muscle tissue, and the visceral (abdominal) space.

Research using MRI-based fat quantification (published in Diabetologia and other journals) shows that hepatic fat accumulation increases measurably years before blood glucose enters the diabetic range. The liver becomes increasingly insulin resistant. Compensatory hyperinsulinemia rises. Eventually, pancreatic beta cells under sustained demand begin to fail.

Treating the fatty liver at this pre-diabetic stage can interrupt the progression to full type 2 diabetes. This is one of the most compelling arguments for early NASH intervention in patients with metabolic syndrome who do not yet have diabetes.

• The “Lean NASH” Phenomenon in Indian Patients

This is the clinically critical point that most Western-focused NASH content misses entirely  and it is directly relevant to Indian patients.

South Asian populations, including Indians, develop metabolic liver disease and insulin resistance at significantly lower BMI thresholds than Western populations. An Indian patient with BMI 23–25, technically within the “normal” range by WHO criteria, may already have significant visceral fat, hepatic steatosis, and insulin resistance.

The conventional “obese patients get NASH” framing does not apply to Indian populations. Indian patients develop NASH at BMI levels that would not trigger concern in a Western clinical setting.

This is why Indian patients with type 2 diabetes and apparently normal weight should still be screened for NASH  and why fibrosis staging should not be deferred simply because the patient does not appear overtly obese.

For patients in Pune, this screening and staging is available through specialist liver disease services at The Liver Transplant, where assessment is tailored to the metabolic risk thresholds relevant to South Asian patients. 

What Does the NASH-Diabetes Combination Do to Cancer Risk?

This is the risk dimension that most patients and much competitor content ignores entirely.

• The Multiplicative HCC Risk

Hepatocellular carcinoma (HCC)  primary liver cancer, develops primarily in patients with cirrhosis from any cause. NASH is an established driver of HCC.

Patients with NASH and concurrent type 2 diabetes have a significantly higher HCC risk than patients with either condition alone. A meta-analysis published in Hepatology found that type 2 diabetes increases HCC risk approximately 2–3 fold independently, and the combination with NASH fibrosis produces a multiplicative rather than simply additive increase in risk.

For patients wanting to understand how to detect liver cancer at its earliest and most treatable stage, particularly relevant for those carrying both NASH and diabetes risk  Is It Possible to Detect Liver Cancer Early? covers the surveillance approaches and warning signs that matter most. 

Critically, HCC has been reported in NASH patients without cirrhosis  a phenomenon rare in other liver diseases. The combination of metabolic inflammation and insulin-driven growth signalling appears sufficient to drive malignant transformation in pre-cirrhotic liver.

NASH patients with type 2 diabetes who have F3 or F4 fibrosis should be enrolled in HCC surveillance (typically 6-monthly liver ultrasound with AFP measurement) and not wait until cirrhosis is formally established.

Which Diabetes Medications Help the Liver?

Not all diabetes drugs have the same effect on NASH, and some patients incorrectly assume that controlling blood sugar automatically treats their liver.

• Metformin: What It Does and Doesn’t Do

Metformin is the most widely used first-line diabetes medication in India. It improves hepatic insulin sensitivity, reduces hepatic glucose output, and modestly reduces liver enzyme levels.

However, metformin does not directly improve NASH histology;  it does not reduce liver inflammation or reverse fibrosis in clinical trials.

Patients on metformin for diabetes should not assume their liver is being treated. Metformin manages blood sugar effectively but does not substitute for dedicated NASH management.

• GLP-1 Receptor Agonists: Dual Benefit

Semaglutide and liraglutide  GLP-1 receptor agonists used for type 2 diabetes and obesity  have shown the most compelling liver benefit among diabetes medications.

Clinical trial data shows significant NASH activity improvement with these agents, and they produce meaningful weight loss that independently benefits the liver. For NASH patients with concurrent type 2 diabetes or obesity, GLP-1 agonists represent the class most likely to simultaneously improve blood sugar control and liver disease.

• SGLT2 Inhibitors: Emerging Hepatic Evidence

Empagliflozin, dapagliflozin, and canagliflozin  SGLT2 inhibitors reduce blood glucose by increasing urinary glucose excretion. They also reduce visceral fat, body weight, and hepatic steatosis in metabolic imaging studies.

Multiple trials have shown reduced liver enzyme levels and reduced hepatic fat fraction on MRI with SGLT2 inhibitors. They are not yet approved specifically for NASH but are reasonable choices in patients who need both glycaemic and liver metabolic management.

• Pioglitazone  The Insulin Sensitiser With Hepatic Evidence

Pioglitazone (a thiazolidinedione) reduces insulin resistance directly and has the strongest histological evidence among non-GLP-1 diabetes agents for NASH improvement, showing reduced liver inflammation and fibrosis in clinical trials.

It is a reasonable choice for NASH patients with type 2 diabetes who cannot tolerate GLP-1 agonists, with the awareness that weight gain and fluid retention are common side effects.

Beyond pharmacological options, targeted nutritional support plays a complementary role in managing NASH in diabetic patients  Role of Vitamins for NASH Treatment explains how specific vitamins and antioxidants fit within the broader NASH treatment framework, particularly for patients with concurrent metabolic disease. 

If you have both type 2 diabetes and fatty liver disease and want a coordinated management plan that addresses both conditions simultaneously, Dr. Bipin Vibhute at thelivertransplant.com provides specialist metabolic hepatology assessment in Pune. Visit thelivertransplant.com to book your consultation.

Can Treating Fatty Liver Improve Diabetes Control?

Yes  and this is one of the most encouraging aspects of the NASH-diabetes bidirectional relationship.

• The Improvement Goes Both Ways

Studies on bariatric surgery  the most powerful intervention for both obesity-related conditions, consistently demonstrate that resolution of fatty liver and NASH precedes or accompanies dramatic improvement in diabetes control, often producing diabetes remission.

Targeted weight loss and NASH treatment reduces hepatic glucose output, improves hepatic insulin sensitivity, and reduces the glycaemic burden that drives beta cell exhaustion. Improving the liver actively improves diabetes, not just the reverse.

For patients exploring what this reversal actually looks like in practice, how much weight loss is needed, at what rate, and what is realistically achievable at each fibrosis stage  Can Weight Loss Reverse NASH? provides the specific clinical thresholds that most patient content omits. 

This bidirectional therapeutic response is the reason that managing both conditions simultaneously, rather than treating diabetes in one clinic and fatty liver in another  produces better outcomes.

Final Thoughts

NASH and type 2 diabetes are not simply comorbid conditions that happen to co-exist. They drive each other through shared metabolic pathways, amplifying both diseases simultaneously.

The fatty liver produces hepatic insulin resistance that drives diabetes. The diabetes produces hyperinsulinemia that drives more liver fat. Breaking this loop requires addressing both conditions simultaneously  not managing them in isolation.

In Indian patients, this relationship begins earlier and at lower body weight than Western clinical frameworks suggest. NASH screening in Indian patients with type 2 diabetes should not wait for obesity to develop.

And for patients with both conditions, the combination carries a liver cancer risk that requires active surveillance, not reassurance.

Frequently Asked Questions

Can NASH cause type 2 diabetes? 

Yes, hepatic fat accumulation impairs the liver’s insulin signalling, causing the liver to overproduce glucose between meals. This hepatic insulin resistance contributes directly to fasting hyperglycaemia and eventually to the development of type 2 diabetes. In many patients, fatty liver and hepatic insulin resistance are present for years before formal diabetes diagnosis  meaning treating fatty liver early may delay or prevent diabetes onset.

Does metformin help with fatty liver disease? 

Metformin improves hepatic insulin sensitivity and modestly reduces liver enzyme levels, but it does not improve NASH histology  it does not reduce liver inflammation or reverse fibrosis in clinical trials. Patients with diabetes and NASH who are on metformin should not assume their liver is being treated. Dedicated NASH management  through lifestyle, weight loss, and in some cases specific pharmacotherapy  is needed alongside diabetes medication.

What blood tests show liver damage in diabetic patients? 

Standard liver function tests (ALT, AST, GGT) and liver synthetic markers (albumin, bilirubin, INR) assess liver injury and function. However, normal liver enzymes do not exclude significant fibrosis  approximately 30% of patients with advanced NASH fibrosis have normal ALT levels. FIB-4 index (calculated from age, AST, ALT, and platelet count) and liver stiffness measurement (FibroScan) are more reliable fibrosis assessments for diabetic patients with fatty liver.

Why do so many diabetic patients have NASH? 

Because insulin resistance  the defining metabolic abnormality of type 2 diabetes  drives hepatic fat overproduction through multiple mechanisms: unregulated hepatic de novo lipogenesis, impaired fat oxidation, and increased free fatty acid flux from peripheral fat stores. Type 2 diabetes increases NASH prevalence to 50–70% compared to 20–30% in the general population. Every type 2 diabetic patient should be screened for NASH, particularly if liver enzymes are elevated or BMI is above 23 in South Asian patients.

Can treating fatty liver put diabetes into remission? 

Treating fatty liver  particularly through significant weight loss or bariatric surgery  can produce dramatic improvements in glycaemic control and, in many patients, formal diabetes remission. Bariatric surgery achieves diabetes remission in 50–80% of patients with type 2 diabetes and obesity, with liver improvement typically preceding or accompanying the glycaemic response. This bidirectional therapeutic response supports treating both conditions simultaneously rather than in isolation.